Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Acorda Therapeutics Inc is a biotechnology business based in the US. Acorda Therapeutics shares (ACOR) are listed on the NASDAQ and all prices are listed in US Dollars. Acorda Therapeutics employs 167 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.65|
|52-week range||$3.27 - $8.66|
|50-day moving average||$4.46|
|200-day moving average||$4.28|
|Wall St. target price||$10.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-14.72|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||3.56%|
|1 month (2021-09-17)||-1.69%|
|3 months (2021-07-19)||28.45%|
|6 months (2021-04-19)||10.45%|
|1 year (2020-10-19)||573.91%|
|2 years (2019-10-18)||89.02%|
|3 years (2018-10-19)||17.86|
|5 years (2016-10-19)||20.05|
Valuing Acorda Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$151.9 million|
|Gross profit TTM||$96.8 million|
|Return on assets TTM||-8.1%|
|Return on equity TTM||-54.85%|
|Market capitalisation||$52.4 million|
TTM: trailing 12 months
There are currently 570,372 Acorda Therapeutics shares held short by investors – that's known as Acorda Therapeutics's "short interest". This figure is 24.7% down from 757,862 last month.
There are a few different ways that this level of interest in shorting Acorda Therapeutics shares can be evaluated.
Acorda Therapeutics's "short interest ratio" (SIR) is the quantity of Acorda Therapeutics shares currently shorted divided by the average quantity of Acorda Therapeutics shares traded daily (recently around 138104.60048426). Acorda Therapeutics's SIR currently stands at 4.13. In other words for every 100,000 Acorda Therapeutics shares traded daily on the market, roughly 4130 shares are currently held short.
However Acorda Therapeutics's short interest can also be evaluated against the total number of Acorda Therapeutics shares, or, against the total number of tradable Acorda Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Acorda Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0612% of the tradable shares (for every 100,000 tradable Acorda Therapeutics shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acorda Therapeutics.
Find out more about how you can short Acorda Therapeutics stock.
We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months.
Acorda Therapeutics's shares were split on a 1:6 basis on 3 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.
Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $3.27 up to $8.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.5799. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).
Acorda Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.